Are Potential Biosimilar Sponsors Still Hesitant About The Pathway Despite Expected Growth?
Executive Summary
IMS Health official says the biologic and biosimilar markets are looming growth areas as small-molecule opportunities decline, but questions about the abbreviated biosimilar pathway linger.
You may also be interested in...
Private Equity Reinvents Its Take On Biopharma
Biopharma offers the best PE returns of any health care sector, but represents only about a third of private equity investment in health care as investors remain wary of high-risk R&D and tend to focus on easier targets, which are in limited supply. As the low-hanging fruit disappears, PE investors are looking at new approaches beyond outright purchases and sorting out opportunities in emerging markets.
GPhA Tactics In Fight Against Calif. Biosimilar Bill Draw FDA Attention
The trade group stopped disseminating an advertisement opposing notification legislation because the agency said it could create confusion about FDA’s stance; GPhA continues to oppose the California measure, which faces an Oct. 13 deadline for the governor’s signature or veto.
FDA, Trying To Build Trust In Biosimilars, Turns To Generics Strategy
GPhA and other opponents of a California prescriber notification bill say an FDA statement on the standards for interchangeability supports their view; statement’s language that efforts to undermine public confidence in biosimilars are “worrisome” mirrors remarks made by FDA Commissioner Hamburg at a GPhA meeting.